ERIOMIN®: The Clinically Studied Ingredient Behind G-Loop™ — And Why It Works for Dogs

What is ERIOMIN®? 

ERIOMIN® is a patented citrus bioflavonoid blend derived from lemon peel, clinically studied in three randomized human trials to increase GLP-1 — the natural hormone that regulates metabolism, digestion, and energy — by 15–22%. It is made by Ingredients by Nature, holds three U.S. patents, and is the active ingredient exclusively powering G-Loop™ for dogs.

Most pet supplements enter the market with a concept, a label claim, and a short list of ingredients that sound credible. Very few enter with over a decade of dedicated research, multiple randomized, placebo-controlled human clinical trials, and several U.S. patents behind a single active compound. ERIOMIN® is the exception. Here's what that research actually shows — and why a decade of human data is directly relevant to your dog.

What makes ERIOMIN® different from other citrus extracts 

Unlike commodity citrus ingredients, ERIOMIN® is standardized to approximately 70% eriocitrin — the specific flavonoid responsible for its mechanism of action in the gut — alongside hesperidin and naringin. That standardization is what makes the clinical results reproducible and the potency consistent from one dose to the next.

It was developed as a human nutraceutical, not a pet supplement afterthought. A decade of dedicated research produced three U.S. patents covering its composition and GLP-1 mechanism — and PETNUTRA holds exclusive global rights for non-human use through 2038. No other pet supplement company can access it.

What the research found

First clinical trial (Ribeiro et al., 2019): Prediabetic patients received 200, 400, or 800 mg per day of ERIOMIN® for 12 weeks in a double-blind, randomized, controlled study. All doses produced consistent results: GLP-1 increased 15%, blood glucose decreased 5%, insulin resistance decreased 7%, and inflammatory markers including IL-6 and TNF-α fell significantly. In 24% of treated patients, prediabetes conditions were reversed. Critically, there was no dose dependence — 200 mg was sufficient to achieve the full effect.¹

Second clinical trial (Cesar et al., 2022): A crossover-randomized trial in prediabetic and diabetic patients found GLP-1 increases of 17%, blood glucose decreases of 5%, and reductions in systemic inflammation including IL-6 at -14% and TNF-α at -20%.²

Third clinical trial (Ramos et al., 2023): A 12-week double-blind, randomized, placebo-controlled trial focused on gut microbiome changes alongside metabolic markers. GLP-1 increased 22%. Blood glucose decreased 6.5%. The microbiome shifted meaningfully — Firmicutes declined, Ruminococcaceae (beneficial bacteria producing short-chain fatty acids) increased by 38%, and markers associated with glycemic dysregulation decreased.³

Across published trials, GLP-1 increases ranged from 15–22%.

Why human research applies to your dog

GLP-1 is not a human-specific hormone. It's produced by every mammal — including your dog — through the same gut mechanisms, serving the same metabolic coordination functions. The biological pathway that ERIOMIN® supports in humans is structurally identical to the pathway in dogs.

This matters because high-quality pet-specific clinical data is rare. Most pet supplements are formulated from human research, and then launched without any direct canine validation. ERIOMIN® is different — it arrives with a decade of human data behind a specific, well-characterized mechanism that operates identically across mammalian species.

 

Canine-specific research is ongoing. The mechanism, the safety profile, and the translational science are already established.

"GLP-1 signaling operates through the same biochemical pathways in dogs as it does in humans. The translational case for ERIOMIN® in canine metabolic support is well-grounded in the existing research."

— Dr. Hariom Yadav, Research Partner, Wake Forest University

The exclusivity is the moat

Three U.S. patents. Global exclusive rights for non-human use through 2038. A proprietary extraction process tied to mature fruit at specific harvest stages.

No other pet supplement can source ERIOMIN®. No competitor can replicate the research profile or the ingredient. This isn't a commodity citrus extract — it's a clinically characterized compound with a protected pathway.

This is where G-Loop™ comes in

G-Loop™ is the only pet supplement powered by ERIOMIN®. Combined with pre-, pro-, and postbiotics and a plant-based saponin complex, each daily stick supports the GLP-1 signaling loop, the gut microbiome, and the cellular signaling that determines how dogs age.

One stick, over your dog's food, every day. The research behind it is the kind most pet supplements never produce.

Explore G-Loop™ → The only pet supplement with ERIOMIN® inside.

 

FAQs

What is eriocitrin, and how does it relate to ERIOMIN®?

Eriocitrin is a citrus flavonoid found primarily in lemon peel. ERIOMIN® is a standardized blend composed of approximately 70% eriocitrin, alongside hesperidin and naringin. The blend is proprietary to Ingredients by Nature and produced through a patented extraction process that standardizes potency and bioavailability.

How many clinical trials has ERIOMIN® completed?

Three published, peer-reviewed human clinical trials — all randomized, double-blind, and placebo-controlled. They were conducted across 12 to 26 weeks in populations with prediabetes and early metabolic dysfunction, which is the same physiological territory where GLP-1 decline matters most in dogs.

What was the average GLP-1 increase across trials?

Across published trials, participants experienced average GLP-1 increases of approximately 15–22% compared to placebo, depending on study design and population.

Why hasn't ERIOMIN® been tested directly in dogs yet?

PETNUTRA holds the exclusive global rights for non-human use and is actively pursuing canine-specific research. Translational research from well-characterized human studies is a standard and accepted pathway in veterinary nutrition when the mechanism is common to both species — and the GLP-1 pathway is.

What makes ERIOMIN® different from other citrus extracts?

The standardization process, the specific eriocitrin concentration, the patent protection, and the accumulated clinical evidence. Citrus extracts are widely available. A patented, clinically validated compound with three human trials and IP protection through 2038 is not.

Citations

1. Ribeiro CB, et al. Effectiveness of Eriomin® in managing hyperglycemia and reversal of prediabetes condition: A double-blind, randomized, controlled study. J Funct Foods. 2019;60:103435.

2. Cesar TB, Ramos FMM, Ribeiro CB. Nutraceutical eriocitrin (Eriomin®) reduces hyperglycemia by increasing glucagon-like peptide 1 and downregulates systemic inflammation: A crossover-randomized clinical trial. J Med Food. 2022;25(11):1050–1058.

3. Ramos FM, Ribeiro CB, Cesar TB, et al. Lemon flavonoids nutraceutical (Eriomin®) attenuates prediabetes intestinal dysbiosis: A double-blind randomized controlled trial. Food Sci Nutr. 2023.